2022
DOI: 10.18502/ijph.v51i7.10098
|View full text |Cite
|
Sign up to set email alerts
|

MiR-205 Regulates LRRK2 Expression in Dopamine Neurons in Parkinson's Disease through Methylation Modification

Abstract: Background: We explored the methylation modification in miR-205 promoter during the pathological changes of Parkinson's disease (PD) and its regulation on Leucine-Rich Repeat Kinase 2 (LRRK2), clarified the important role of methylation in miR-205 promoter region in PD, explained the role of miR-205 methylation in the pathological changes of PD, and looked for new targets for PD. Methods: Methylation of miR-205 promoter regions was determined by cell genomic DNA, with model bisulfite treatment, and the t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 30 publications
0
2
0
Order By: Relevance
“…cells of the PD model. The findings from the methylation inhibition assay demonstrate that hypomethylation of the miR-205 promoter region effectively suppresses LRRK2 expression (Wang et al, 2022). MiR-6800 level was significant higher in L2NMC (LRRK2 non-manifesting carriers) than in L2PD (LRRK2 carrier with symptomatic PD) (Soto et al, 2023), which implies that miR-6800 have a significantly protective effect on PD.…”
Section: Discussionmentioning
confidence: 88%
“…cells of the PD model. The findings from the methylation inhibition assay demonstrate that hypomethylation of the miR-205 promoter region effectively suppresses LRRK2 expression (Wang et al, 2022). MiR-6800 level was significant higher in L2NMC (LRRK2 non-manifesting carriers) than in L2PD (LRRK2 carrier with symptomatic PD) (Soto et al, 2023), which implies that miR-6800 have a significantly protective effect on PD.…”
Section: Discussionmentioning
confidence: 88%
“…Comparing cellular, EV-enriched preparations, and EV luminal RNAs using miRNA-seq, we identified a selection of miRNAs preferentially secreted and protected from proteinase K and RNase A/T1 treatment, indicating that they are likely transported inside EVs. Even though this should be taken with some caution because the preferentially secreted miRNAs included several miRNAs without experimentally validated targets ( Table S4 ), GO annotations of their target mRNA point to preferentially secreted miRNAs protected inside EVs as being good candidates to drive the reported effects of astrocyte EVs in neuronal processes, such as cell survival and axon regeneration [ 9 , 73 ]; miR-203 has been reported to play a role in neuronal cell death and the regulation of neuronal activity [ 74 ], and miR-205 has been reported to modulate the expression of the leucine-rich repeat kinase 2 (LRRK2) gene which is involved in Parkinson’s disease [ 75 ]. MiR-21, involved, among other roles, in neuronal repair and transferred by EVs in the brain [ 7 , 13 , 76 ] is not significantly different between cells and the EV lumen and miR-23, which is equally distributed in cells, and EVs are involved in myelination and neuronal differentiation [ 15 , 16 ].…”
Section: Discussionmentioning
confidence: 99%